





AMENDMENTS TO THE CLAIMS – AMENDMENT B



This Listing of Claims will replace all prior versions and listings of claims in this application.








Listing of Claims:







1.-11. (Canceled).






12. **(Currently Amended)** A method of treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:








943	
944	
945	
946	






947	
948	







949	
950	
951	
952	
953	
954	
955	








956	
957	
958	
959	
960	
961	








962	CHIRAL 
963	 chiral (+)
964	CHIRAL 
965	CHIRAL 
966	CHIRAL 






967	CHIRAL 
968	
969	
970	
971	
972	
973	




974	 chiral (+)
975	 chiral (+)
976	 chiral (+)
977	 chiral (+)
978	 chiral (-)

979	 chiral (+)
980	 chiral (+)
981	 chiral (+)
982	 chiral (+)
983	 chiral (+)
984	 chiral (+)

985	
986	
987	
988	
989	
990	
991	

992	
993	
994	
995	
996	
997	
998	

999	
1000	
1001	
1002	
1003	

1004	
1005	
1006	

wherein the disorder is selected from the group consisting of neurological disorders, psychiatric disorders, chronic and acute pain disorders, gastrointestinal disorders, Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatoid diseases, low back pain, post-operative pain, pain associated with angina, renal and

billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

13. **(Original)** The method according to claim 12, wherein the disorder is a neurological disorder.

14. **(Original)** The method according to claim 12, wherein the disorder is a psychiatric disorder.

15. **(Original)** The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders.

16. **(Original)** The method according to claim 12, wherein the disorder is a gastrointestinal disorder.

17. **(Original)** The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, ophthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

18. **(Canceled).**